This HTML5 document contains 53 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n17http://linked.opendata.cz/ontology/domain/vavai/riv/statVydaniPatentuVzoru/
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/domain/vavai/projekt/
n4http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n21http://linked.opendata.cz/ontology/domain/vavai/riv/uzemniOchranaPatentu/
n5http://linked.opendata.cz/ontology/domain/vavai/
n9http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F61389030%3A_____%2F10%3A00353545%21RIV11-GA0-61389030/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/vyuzitiPatentuVzoru/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/licencniPoplatek/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n19http://linked.opendata.cz/ontology/domain/vavai/riv/vyuzitiJinymSubjektem/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n20http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n8http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F61389030%3A_____%2F10%3A00353545%21RIV11-GA0-61389030
rdf:type
n5:Vysledek skos:Concept
dcterms:description
The present invention relates to a compound of formula I, or a pharmaceutically acceptable acid salt thereof. The invention further relates to the use of such compounds in the treatment of hyperproliferative skin disorders, viral infections, cancer, rheumatoid arthritis, lupus, type I diabetes, multiple sclerosis, restenosis, polycystic kidney disease, graft rejection, graft versus host disease and gout, or for psoriasis, parasitoses such as those caused by fungi or protists, or Alzheimer's disease.Further aspects of the invention relate to the use of such compounds in the inhibition of cell proliferation, in the induction of apoptosis, to modulate the activity of adrenergic and/or purinergic receptors or to suppress immunostimulation. The invention also relates to the use of 2,6,9-trisubstituted 8-azapurines in maintaining mammalian ooctyes at the germinal vesicle stage. The present invention relates to a compound of formula I, or a pharmaceutically acceptable acid salt thereof. The invention further relates to the use of such compounds in the treatment of hyperproliferative skin disorders, viral infections, cancer, rheumatoid arthritis, lupus, type I diabetes, multiple sclerosis, restenosis, polycystic kidney disease, graft rejection, graft versus host disease and gout, or for psoriasis, parasitoses such as those caused by fungi or protists, or Alzheimer's disease.Further aspects of the invention relate to the use of such compounds in the inhibition of cell proliferation, in the induction of apoptosis, to modulate the activity of adrenergic and/or purinergic receptors or to suppress immunostimulation. The invention also relates to the use of 2,6,9-trisubstituted 8-azapurines in maintaining mammalian ooctyes at the germinal vesicle stage.
dcterms:title
Substituted [1,2,3]triazolo[4,5-D]pyrimidines as CDK inhibitors Substituted [1,2,3]triazolo[4,5-D]pyrimidines as CDK inhibitors
skos:prefLabel
Substituted [1,2,3]triazolo[4,5-D]pyrimidines as CDK inhibitors Substituted [1,2,3]triazolo[4,5-D]pyrimidines as CDK inhibitors
skos:notation
RIV/61389030:_____/10:00353545!RIV11-GA0-61389030
n3:aktivita
n15:P
n3:aktivity
P(GA301/08/1649), P(KAN200380801)
n3:cisloPatentuVzoru
US7816350
n3:datumUdeleniPatentuVzoru
2010-10-19+02:00
n3:dodaniDat
n8:2011
n3:domaciTvurceVysledku
n4:9130241 n4:9961216 n4:9896821 n4:7626843 n4:4712048
n3:druhVysledku
n6:P
n3:duvernostUdaju
n20:S
n3:entitaPredkladatele
n9:predkladatel
n3:idSjednocenehoVysledku
290971
n3:idVysledku
RIV/61389030:_____/10:00353545
n3:jazykVysledku
n11:eng
n3:klicovaSlova
Substituted [1,2,3]triazolo[4,5-D]pyrimidines; CDK; inhibitors
n3:klicoveSlovo
n7:Substituted%20%5B1 n7:inhibitors n7:2 n7:CDK n7:5-D%5Dpyrimidines n7:3%5Dtriazolo%5B4
n3:kontrolniKodProRIV
[5F4E331917C1]
n3:licencniPoplatek
n13:A
n3:mistoVydaniPatentuVzoru
Alexandria
n3:nazevVydavatelePatentuVzoru
United States Patent and Trademark Office http://v3.espacenet.com/publicationDetails/originalDocument?FT=D&date=20101019&DB=EPODOC&locale=en_EP&CC=US&NR=7816350B2&KC=B2
n3:obor
n12:FD
n3:pocetDomacichTvurcuVysledku
5
n3:pocetTvurcuVysledku
5
n3:projekt
n16:GA301%2F08%2F1649 n16:KAN200380801
n3:rokUplatneniVysledku
n8:2010
n3:statVydaniPatentuVzoru
n17:US
n3:tvurceVysledku
Lenobel, René Kryštof, Vladimír Havlíček, Libor Fuksová, Květa Strnad, Miroslav
n3:uzemniOchranaPatentu
n21:B
n3:vlastnik
n9:vlastnikVysledku
n3:vyuzitiJinymSubjektem
n19:A
n3:vyuzitiPatentuVzoru
n14:B
n3:vlastnikPatentuVzoru
Ústav experimentální botaniky AV ČR, v. v. i., Univerzita Palackého v Olomouci